港股异动丨圣诺医药高开近15%，治疗原位鳞状细胞癌疗法获FDA具体指导建议

格隆汇资讯04-17

圣诺医药-B(2257.HK)高开14.95%报6.92港元。消息面上，公司公布已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。所要求的C类会议的目的是获得FDA对拟议的非临床和临床开发计划的建议和意见，为治疗isSCC的II/III期及III期临床研究作准备。针对公司的建议以及与相关非临床研究及临床研究...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428399173?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-17 09:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2428399173","market":"hk","top_or_hot":-1,"title":"港股异动丨圣诺医药高开近15%，治疗原位鳞状细胞癌疗法获FDA具体指导建议","media":"格隆汇资讯","content":"<div>\n<p>圣诺医药-B(2257.HK)高开14.95%报6.92港元。消息面上，公司公布已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。所要求的C类会议的目的是获得FDA对拟议的非临床和临床开发计划的建议和意见，为治疗isSCC的II/III期及III期临床研究作准备。针对公司的建议以及与相关非临床研究及临床研究...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170925548b2c9cac&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动丨圣诺医药高开近15%，治疗原位鳞状细胞癌疗法获FDA具体指导建议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动丨圣诺医药高开近15%，治疗原位鳞状细胞癌疗法获FDA具体指导建议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 09:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170925548b2c9cac&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>圣诺医药-B(2257.HK)高开14.95%报6.92港元。消息面上，公司公布已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。所要求的C类会议的目的是获得FDA对拟议的非临床和临床开发计划的建议和意见，为治疗isSCC的II/III期及III期临床研究作准备。针对公司的建议以及与相关非临床研究及临床研究...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170925548b2c9cac&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02257","symbol_name":"圣诺医药-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170925548b2c9cac&s=b","article_id":"2428399173","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170925548b2c9cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2428399173","pubTimestamp":1713317125,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"圣诺医药-B高开14.95%报6.92港元。消息面上，公司公布已获得美国食品药监局关于其用于进一步研发治疗原位鳞状细胞癌的新型siRNA疗法STP705所要求的C类会议的书面答复。针对公司的建议以及与相关非临床研究及临床研究设计有关的问题，FDA已为非临床及临床研究、对拟议的II/III期及III期临床研究的修订，以及在候选药物STP705中使用两种活性成分所需的进一步论证提供明确的具体指导建议。目前，公司已根据FDA的指导建议启动所需的临床前研究。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02257":"圣诺医药-B","BK1161":"生物科技","07226":"XL二南方恒科"},"translate_title":"Hong Kong stocks changed, Shengnuo Pharmaceuticals opened nearly 15% higher, and the treatment of squamous cell carcinoma in situ received specific guidance from the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":1,"07226":1},"content_text":"圣诺医药-B(2257.HK)高开14.95%报6.92港元。消息面上，公司公布已获得美国食品药监局(FDA)关于其用于进一步研发治疗原位鳞状细胞癌(isSCC)的新型siRNA疗法STP705所要求的C类会议的书面答复。所要求的C类会议的目的是获得FDA对拟议的非临床和临床开发计划的建议和意见，为治疗isSCC的II/III期及III期临床研究作准备。针对公司的建议以及与相关非临床研究及临床研究设计有关的问题，FDA已为非临床及临床研究、对拟议的II/III期及III期临床研究的修订，以及在候选药物STP705中使用两种活性成分所需的进一步论证提供明确的具体指导建议。目前，公司已根据FDA的指导建议启动所需的临床前研究。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428399173"}